StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by MrMaker1111on Mar 28, 2019 3:53pm

140 Views

Post# 29550411

RE:Market And The News

Goldy, I agree with you here. Not to be overall optimistic but if you look at the investor presentation slide https://www.genenews.com/investor-presentation.html, It clearly states healthcare system alone is a 36M opportunity over 12 months.. DTC isn't built into that. Maybe or likely? none of these other sales channels will really kick in until 2020.. Slide states Dec 2019 for Concerige Med and High risk employee opportunites... If say PNW is truely operational in the coming months muy bien amigos! Havent sold a single share.

Lets get it GEN!

Cheers!

Bullboard Posts

Visionstate set to leverage success in the U.S. market